Skip to content
Why we work on Alzheimer’s disease episode artwork

Nov 30, 2016 6 min

Why we work on Alzheimer’s disease

from Translational and Clinical

Housed within the Target Discovery Institute, the Alzheimer’s Research UK Oxford Drug Discovery Institute (ODDI) juxtaposes drug discovery expertise alongside scientific and academic understanding of patients, disease mechanisms and model systems. The burden caused by Alzheimer’s disease and other dementias represents one of the biggest problems for our healthcare systems. The last medicine was approved in 2002 and today we only have symptomatic treatments. ARUK-ODDI brings together chemists, biologist, psychiatrists and neuroscientists, many of them with pharmaceutical background, aiming to accelerate the discovery of novel and effective treatments.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Why we work on Alzheimer’s disease

0:00 6:30

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Translational and Clinical?

This episode is 6 minutes long.

When was this Translational and Clinical episode published?

This episode was published on November 30, 2016.

Can I download this Translational and Clinical episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.